Effect of Omega 3 as an Immunomodulator Adjunct to Periodontal Debridement
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of the systemic administration of Omega 3 as a therapy
associated with non-surgical periodontal treatment, in the clinical and microbiological
variables of patients with Moderate Periodontitis with moderate rate of progression (Stage II
grade B) and Severe Periodontitis with potential for additional tooth loss and moderate rate
of progression (Stage III grade B). A double-blind, randomized, controlled trial was
conducted with 18 voluntary patients with a history of moderate to severe chronic
periodontitis, who met the inclusion and exclusion criteria and signed an informed consent.
The intervention group received Scaling and Root Planning (SRP) plus Omega 3, and the control
group received SRP plus placebo. Probing depth (PD), Clinical Attachment Level (CAL), Biofilm
Index (BI) and Bleeding on Probing (BOP) were evaluated as clinical variables while
Porphyromonas gingivalis (Pg), Tannerella forsythia (Tf), Treponema denticola (Td),
Fusobacterium nucleatum (Fn) were the microbiological variables detected by conventional
Polymerase chain reaction (PCR).